Clinical Research Directory

Inclusion Criteria: * ECOG performance status 0-1 * Life expectancy \>6 months * Number of lesions: ≤ 3 * Lesion size : \< 10 cm for a single lesion (and up to 10 cm cumulative diameter for multiple lesions) * Child-Pugh A or B7 within 6 weeks prior to study entry * Unsuitable for RFA or resection or transplant * Distance from GTV to luminal structures (i.e., oesophagus, stomach, duodenum, small or large bowel) ≥ 10mm * All blood work obtained within 6 weeks prior to study entry with adequate organ function * May have had previous surgery, RFA or ethanol injection * Patient must have been discussed at multidisciplinary tumour board with consensus opinion for SBRT Exclusion Criteria: * HCC/cholangiocarcinoma with evidence of metastatic disease including nodal or distant metastases * Metastatic disease with complete liver disease response to first-line chemotherapy (i.e. no target for SBRT) * Previous radiation to the liver (including SIRTEX) * Untreated HIV or active hepatitis B/C * On systemic antineoplastic drug therapy within 7 days before inclusion * Pregnant or lactating women